ASCO Annual Meeting

Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL

June 9th 2025, 4:01pm

Article

The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.

Targeted Chemo Improves Survival in Early-Stage Lung Cancer

June 8th 2025, 2:00pm

Article

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.

KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety

June 7th 2025, 2:00pm

Article

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.

Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation

June 6th 2025, 9:00pm

Article

Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.

Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer

June 6th 2025, 8:00pm

Video

Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.

Columvi Combo Enhances Survival Outcomes in R/R Lymphoma Subgroup

June 5th 2025, 4:00pm

Article

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.

Nubeqa Combo Positively Impacts HRQoL vs Placebo in Prostate Cancer Subgroup

June 4th 2025, 4:00pm

Article

Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer.

Rina-S Yields 50% Response Rate in Advanced Endometrial Cancer

June 4th 2025, 3:00pm

Article

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.

Imdelltra Shows Survival Benefit in Small Cell Lung Cancer

June 3rd 2025, 9:00pm

Article

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, reinforcing it as a new SOC.

Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer

June 3rd 2025, 8:00pm

Video

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.